146 related articles for article (PubMed ID: 35260349)
1. A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.
Zeidan AM; Cook RJ; Bordoni R; Berenson JR; Edenfield WJ; Mohan S; Zhou G; Asatiani E; Srinivas N; Savona MR
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):523-534. PubMed ID: 35260349
[TBL] [Abstract][Full Text] [Related]
2. Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study.
Naing A; Powderly JD; Nemunaitis JJ; Luke JJ; Mansfield AS; Messersmith WA; Sahebjam S; LoRusso PM; Garrido-Laguna I; Leopold L; Geschwindt R; Ding K; Smith M; Berlin JD
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288468
[TBL] [Abstract][Full Text] [Related]
3. The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
Moyo TK; Mendler JH; Itzykson R; Kishtagari A; Solary E; Seegmiller AC; Gerds AT; Ayers GD; Dezern AE; Nazha A; Valent P; van de Loosdrecht AA; Onida F; Pleyer L; Cirici BX; Tibes R; Geissler K; Komrokji RS; Zhang J; Germing U; Steensma DP; Wiseman DH; Pfeilstöecker M; Elena C; Cross NCP; Kiladjian JJ; Luebbert M; Mesa RA; Montalban-Bravo G; Sanz GF; Platzbecker U; Patnaik MM; Padron E; Santini V; Fenaux P; Savona MR;
BMC Cancer; 2022 Sep; 22(1):1013. PubMed ID: 36153475
[TBL] [Abstract][Full Text] [Related]
4. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Watts JM; Baer MR; Yang J; Prebet T; Lee S; Schiller GJ; Dinner SN; Pigneux A; Montesinos P; Wang ES; Seiter KP; Wei AH; De Botton S; Arnan M; Donnellan W; Schwarer AP; Récher C; Jonas BA; Ferrell PB; Marzac C; Kelly P; Sweeney J; Forsyth S; Guichard SM; Brevard J; Henrick P; Mohamed H; Cortes JE
Lancet Haematol; 2023 Jan; 10(1):e46-e58. PubMed ID: 36370742
[TBL] [Abstract][Full Text] [Related]
5. Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies.
Patel MR; Donnellan W; Byrne M; Asch AS; Zeidan AM; Baer MR; Fathi AT; Kuykendall AT; Zheng F; Walker C; Cheng L; Marando C; Savona MR
Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):674-686. PubMed ID: 37290996
[TBL] [Abstract][Full Text] [Related]
6. A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus
Beatty GL; Shahda S; Beck T; Uppal N; Cohen SJ; Donehower R; Gabayan AE; Assad A; Switzky J; Zhen H; Von Hoff DD
Oncologist; 2019 Jan; 24(1):14-e10. PubMed ID: 30115734
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.
Phillips TJ; Forero-Torres A; Sher T; Diefenbach CS; Johnston P; Talpaz M; Pulini J; Zhou L; Scherle P; Chen X; Barr PM
Blood; 2018 Jul; 132(3):293-306. PubMed ID: 29695516
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Kirschbaum M; Gojo I; Goldberg SL; Bredeson C; Kujawski LA; Yang A; Marks P; Frankel P; Sun X; Tosolini A; Eid JE; Lubiniecki GM; Issa JP
Br J Haematol; 2014 Oct; 167(2):185-93. PubMed ID: 25040094
[TBL] [Abstract][Full Text] [Related]
9. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
Savona MR; Kolibaba K; Conkling P; Kingsley EC; Becerra C; Morris JC; Rifkin RM; Laille E; Kellerman A; Ukrainskyj SM; Dong Q; Skikne BS
Am J Hematol; 2018 Oct; 93(10):1199-1206. PubMed ID: 30016552
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.
Garcia-Manero G; Tibes R; Kadia T; Kantarjian H; Arellano M; Knight EA; Xiong H; Qin Q; Munasinghe W; Roberts-Rapp L; Ansell P; Albert DH; Oliver B; McKee MD; Ricker JL; Khoury HJ
Invest New Drugs; 2015 Aug; 33(4):870-80. PubMed ID: 25933833
[TBL] [Abstract][Full Text] [Related]
11. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
Abaza YM; Kadia TM; Jabbour EJ; Konopleva MY; Borthakur G; Ferrajoli A; Estrov Z; Wierda WG; Alfonso A; Chong TH; Chuah C; Koh LP; Goh BC; Chang JE; Durkes DE; Foudray MC; Kantarjian HM; Dong XQ; Garcia-Manero G
Cancer; 2017 Dec; 123(24):4851-4859. PubMed ID: 28841236
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial.
Zeiser R; Socié G; Schroeder MA; Abhyankar S; Vaz CP; Kwon M; Clausen J; Volodin L; Giebel S; Chacon MJ; Meyers G; Ghosh M; Deeren D; Sanz J; Morariu-Zamfir R; Arbushites M; Lakshminarayanan M; Barbour AM; Chen YB
Lancet Haematol; 2022 Jan; 9(1):e14-e25. PubMed ID: 34971577
[TBL] [Abstract][Full Text] [Related]
14. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
[TBL] [Abstract][Full Text] [Related]
15. Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine.
Handa H; Cheong JW; Onishi Y; Iida H; Kobayashi Y; Kim HJ; Chiou TJ; Izutsu K; Tsukurov O; Zhou X; Faessel H; Yuan Y; Sedarati F; Faller DV; Kimura A; Wu SJ
J Hematol Oncol; 2022 May; 15(1):56. PubMed ID: 35545778
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants.
Gong X; Darpo B; Xue H; Punwani N; He K; Barbour AM; Epstein N; Landman R; Chen X; Yeleswaram S
Clin Pharmacol Drug Dev; 2020 Aug; 9(6):677-688. PubMed ID: 31821750
[TBL] [Abstract][Full Text] [Related]
17. Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis.
Avci AB; Feist E; Burmester GR
Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii11-ii16. PubMed ID: 33950228
[TBL] [Abstract][Full Text] [Related]
18. Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms.
Tibes R; Kosiorek HE; Dueck AC; Palmer J; Sproat L; Bogenberger J; Hashmi S; Mesa R; Hogan W; Litzow MR; Al-Kali A
Cancer; 2023 Aug; 129(15):2321-2330. PubMed ID: 37042080
[TBL] [Abstract][Full Text] [Related]
19. A systematic review and meta
Kunacheewa C; Thongthang P; Ungprasert P; Utchariyaprasit E; Owattanapanich W
Hematology; 2019 Dec; 24(1):498-506. PubMed ID: 31221030
[TBL] [Abstract][Full Text] [Related]
20. Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.
Zhou X; Friedlander S; Kupperman E; Sedarati F; Kuroda S; Hua Z; Yuan Y; Yamamoto Y; Faller DV; Haikawa K; Nakai K; Bowen S; Dai Y; Venkatakrishnan K
Clin Transl Sci; 2021 May; 14(3):1069-1081. PubMed ID: 33503305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
